Want to see OKYO full AI Analyst Report?
Top Page
OKYO Pharma Limited Sponsored ADR
(NASDAQ:OKYO)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:Reiterated
Date:07/22/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow implying continued funding needs). Technical indicators also lean bearish with price below key moving averages and a negative MACD, despite oversold conditions. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Regulatory clarity for Phase 3
Direct FDA alignment on a single-dose Phase 3 registrational design materially reduces program regulatory risk. This durable regulatory clarity supports an efficient pivotal path, increases likelihood of a streamlined review, and meaningfully de-risks time-to-market and strategic planning for the lead asset.
Negative Factors
Pre-revenue profile
As a development-stage biotech with zero product revenue, long-term value depends entirely on clinical success, approvals, or non-dilutive partnerships. This structural absence of operating income means ongoing reliance on capital markets or deals until commercialization, elevating execution and financing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity for Phase 3
Direct FDA alignment on a single-dose Phase 3 registrational design materially reduces program regulatory risk. This durable regulatory clarity supports an efficient pivotal path, increases likelihood of a streamlined review, and meaningfully de-risks time-to-market and strategic planning for the lead asset.
Read all positive factors
OKYO Pharma Limited Sponsored ADR (OKYO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$88.17M
Dividend YieldN/A
Average Volume (3M)131.52K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue GrowthN/A
EPS Growth-39.90%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,479,527
10 Day Avg. Volume47,624
30 Day Avg. Volume131,524
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-10.12
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.88K
Enterprise Value/Ebitda-8.77
Forecast
1Y Price Target
$5.00Price Target Upside201.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model
Company Description
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary the...
How the Company Makes Money
null...
OKYO Pharma Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -2.56K | 0.00 | -6.75M | -13.00K |
| EBITDA | -8.47M | -7.08M | -15.75M | -13.08M | -6.21M |
| Net Income | -8.95M | -4.71M | -16.83M | -13.27M | -5.43M |
Balance Sheet | |||||
| Total Assets | 20.98M | 3.68M | 1.54M | 5.20M | 4.30M |
| Cash, Cash Equivalents and Short-Term Investments | 20.59M | 1.56M | 826.85K | 4.05M | 2.70M |
| Total Debt | 0.00 | 0.00 | 0.00 | 2.22M | 0.00 |
| Total Liabilities | 8.64M | 9.23M | 7.42M | 7.26M | 1.35M |
| Stockholders Equity | 12.34M | -5.55M | -5.88M | -2.05M | 2.95M |
Cash Flow | |||||
| Free Cash Flow | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M |
| Operating Cash Flow | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M |
| Investing Cash Flow | -6.01M | -1.21K | 0.00 | -5.92K | -1.67K |
| Financing Cash Flow | 25.02M | 2.66M | 6.21M | 9.32M | 2.15M |
OKYO Pharma Limited Sponsored ADR Technical Analysis
Positive
1.66
Price Trends
1.59
Positive
1.60
Positive
1.86
Negative
Market Momentum
0.02
Negative
57.93
Neutral
77.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKYO, the sentiment is Positive. The current price of 1.66 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.59, and below the 200-day MA of 1.86, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.93 is Neutral, neither overbought nor oversold. The STOCH value of 77.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OKYO.
OKYO Pharma Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
OKYO
OKYO Pharma Limited Sponsored ADR
1.67
-1.50
-47.32%
ALDX
Aldeyra Therapeutics
1.53
-3.63
-70.35%
OKYO Pharma Limited Sponsored ADR Corporate Events
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
Jul 28, 2026
OKYO Pharma reported on July 28, 2026, that its Chief Scientific Officer, Raj Patil, purchased 3,363 ordinary shares on Nasdaq at $1.49 each, increasing his total holdings to 20,030 shares. The share purchase by a senior scientific executive may s...
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
Jul 27, 2026
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases. Listed on the Nasdaq Capital Market, it plans to begin a global Phase 3 pivotal trial in the second half of 20...
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
Jul 23, 2026
On July 23, 2026, OKYO Pharma announced that non-executive director John Brancaccio purchased 5,000 ordinary shares on Nasdaq at $1.48 per share, increasing his total holding to 35,201 shares. The director’s share purchase underscores inside...
OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase
Jul 23, 2026
On July 23, 2026, OKYO Pharma announced that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at a price of $1.54 per share. The insider purchase, disclosed via a Form 6-K filing, underscores dire...
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial
Jul 22, 2026
On July 22, 2026, OKYO Pharma announced that Chairman Gabriele Cerrone, via Panetta Partners Ltd, increased his stake in the company by purchasing 22,500 ordinary shares at $1.45 each. This transaction lifted his total holding to 10,873,916 shares...
OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial
Jul 22, 2026
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on innovative treatments for neuropathic corneal pain and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market. The company intends to...
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial
Jul 22, 2026
OKYO Pharma Limited, a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market, is developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases. The company plans to initiate a global Pha...
OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial
Jul 21, 2026
On July 21, 2026, OKYO Pharma announced it will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, with Chief Executive Officer Robert J. Dempsey and Chief Medical Officer Flavio Mantelli leading the sessi...
OKYO Pharma Chairman Boosts Stake Ahead of Phase 3 Neuropathic Corneal Pain Trial
Jul 21, 2026
On July 21, 2026, OKYO Pharma Limited reported that Chairman Gabriele Cerrone, via Panetta Partners Ltd, increased his stake by purchasing 25,000 ordinary shares at $1.40 each. This transaction lifted his total holding to 10,851,416 ordinary share...
OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial
Jul 20, 2026
On July 20, 2026, OKYO Pharma filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission, accompanied by a corporate update highlighting stronger finances and advancing clinical p...
OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain
Jul 8, 2026
OKYO Pharma Limited, a clinical-stage biopharmaceutical company listed on Nasdaq, is developing urcosimod as a first-in-class, non-opioid treatment for neuropathic corneal pain and anterior segment eye diseases. The drug, a chemerin peptide agonis...
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
Jul 7, 2026
OKYO Pharma Limited, a Nasdaq-listed clinical-stage biopharmaceutical company, is developing therapies for neuropathic corneal pain and inflammatory eye diseases, with a strategic focus on novel ocular molecules. The company recently completed a s...
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain
May 19, 2026
On May 19, 2026, OKYO Pharma announced it has expanded its Scientific Advisory Board by appointing Italian ophthalmologist Marta Sacchetti, MD, PhD, an associate professor at Link University in Rome and former Global Head of Clinical Development, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.